In July 2026, CSC Financial covered Mininglamp Technology for the first time and granted it a "Buy" rating. The firm believes that the company is at a critical period of strategic transformation from traditional data intelligence to Agentic AI, and that its new business, Agentic Services, delivered high growth immediately upon its launch in the second half of last year.
NewTimeSpace (newtimespace.com) reported that on July 3, 2026, the robotics theme continued to strengthen, with UBTECH (09880.HK) rising sharply. As of 13:37, the stock was quoted at HKD 105.400, up 13.82%.
NewTimeSpace News: June 30, 2026, MAGNUSCONCORDIA(01172.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 110.17 million, decreased by 9.92% YoY
NewTimeSpace (newtimespace.com) News, QINGSONG HEALTH(02661.HK) will spend HKD 29.89 million to repurchase 2.97 million shares on Jul 2, 2026.
NewTimeSpace (newtimespace.com) News, BABA-W(09988.HK) will spend USD 49.99 million to repurchase 4.06 million shares on Jul 1, 2026.
NewTimeSpace (newtimespace.com) News, CHINA HUAJUN GP (00377.HK) plans to issue in total 12 million shares by subscription, with estimated net proceeds of HKD 13 million.
NewTimeSpace (newtimespace.com) News, XUNCE (03317.HK) plans to issue in total 7.28 million shares by placement, with estimated net proceeds of HKD 771 million.
NewTimeSpace (newtimespace.com) News, 51WORLD (06651.HK) plans to issue in total 5.47 million shares by placement, with estimated net proceeds of HKD 394.5 million.
NewTimeSpace News: Inkeverse announced on July 2 that the preconditions under six subscription agreements have been satisfied, with partial completion effected on July 2. A total of 192,488,400 subscription shares have been allotted and issued, generating net proceeds of approximately HK$164 million intended for the purchase of high-performance GPUs and construction of GPU computing infrastructure.
NewTimeSpace News: Conant Optics announced on July 2 that the Company redeemed wealth management products issued by Huatai International on January 30 and July 2 for USD 10 million and USD 20 million respectively, generating unaudited accrued interest income of approximately USD 652,000 in aggregate.
NewTimeSpace News: Dobot announced on July 2 that the trustee purchased 100,000 H-shares on the market on the same day under the H-share incentive scheme at a price ranging from approximately HK$25.40 to HK$25.60 per share, with total consideration of around HK$2.5485 million.
NewTimeSpace News: Tigermed announced on July 2 that as of June 30, the Company had repurchased a total of 20,963,478 A-shares through centralized bidding transactions, accounting for 2.4347% of the Company’s total share capital, with a total transaction value of approximately RMB 824 million.
NewTimeSpace News: Zhongshen Jianye Holdingannounced on July 2 that its rights issue on the basis of two rights shares for every one existing share held has achieved full 100% subscription. The unsubscribed portion of 525,531,870 rights shares was successfully placed to seven placees via a compensation arrangement, raising total gross proceeds of approximately HK$343 million.
NewTimeSpace News: Zenergy Battery Technologiesannounced on July 2 that the Company has resolved to launch its application for listing on ChiNext of the Shenzhen Stock Exchange. It has signed a listing tutorship agreement with Guotai Haitong Securities and submitted the filing application for A-share listing tutorship.
NewTimeSpace News: Zhejiang Expressway announced on July 2 that Mr. Bei Kewei and Ms. Li Weizheng had tendered their resignations as independent non-executive directors, as their respective consecutive tenures have exceeded six years, which fails to comply with relevant regulatory guidelines of the Shanghai Stock Exchange.
NewTimeSpace News: EDDING GENOR GROUPannounced in a July 2 announcement that the Investigational New Drug (IND) application for GB268, its highly differentiated innovative PD-1/CTLA-4/VEGF trispecific antibody, has been approved by the National Medical Products Administration (NMPA) for a Phase Ib/II clinical trial treating locally advanced unresectable or metastatic breast cancer.
